Company Filing History:
3 out of 525 
1 out of 185 
2 out of 832,891 Years Active: 2001-2009
Title: Innovations and Contributions of Kris Thielemans
Introduction
Kris Thielemans is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of biomedical research, particularly in the area of cancer immunotherapy. With a total of 5 patents to his name, Thielemans has focused on developing innovative solutions that enhance the understanding and treatment of cancer.
Latest Patents
Among his latest patents is an invention related to an isolated peptide that binds to HLA-Cw*07. This peptide consists of amino acid sequences found in MAGEA3, which bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic implications of this invention are profound, as they pave the way for various products developed during the invention's progression. Another significant patent involves MAGE-3 peptides presented by HLA class II molecules. This invention describes HLA class II binding peptides encoded by the MAGE-3 tumor-associated gene, along with nucleic acids encoding such peptides and related antibodies. These peptides stimulate the activity and proliferation of CD4T lymphocytes, providing methods and products for diagnosing and treating conditions characterized by the expression of the MAGE-3 gene.
Career Highlights
Kris Thielemans has worked with the Ludwig Institute for Cancer Research Limited, where he has contributed to groundbreaking research in cancer treatment. His work has been instrumental in advancing the understanding of tumor-associated antigens and their role in immune response.
Collaborations
Throughout his career, Thielemans has collaborated with notable professionals in the field, including Pascal Chaux and Vincent Stroobant. These collaborations have further enriched his research and innovations.
Conclusion
Kris Thielemans is a distinguished inventor whose work has significantly impacted cancer research and treatment. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.